Skip to main content

Table 1 Kinetic data for lysoPC inhibition of sPLA2 activity in plasma

From: Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties

Plasma Treatment

Vmax (nM/min/ml)

Km (μM)

R2

Ki ± s.e.m. (μM)

Vehicle

1296

33.24

0.9938

 

Palmitoyl

684.7

16.12

0.9595

25.9 ± 4.0

Vehicle

1395

27.24

0.9413

 

Stearoyl

669.2

11.26

0.928

34.2 ± 17.4

  1. Data from enzyme reactions of plasma samples containing lysoPC (20 μM) or vehicle. The reactions for each lysoPC–containing sample were run side by side with vehicle-containing samples and they were drawn from the same pool of plasma. In each case the lysoPC reduced both Km and Vmax showing the inhibition was uncompetitive. Average Ki values with s.e.m. were calculated as in previous studies from all reactions with substrates above 15 μM [23]. R2 = fit to Michaelis-Menten function.